Canaccord Genuity Reiterates Buy on Radius Health (RDUS) Following ASBMR Presentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Radius Health Presents Positive Phase 3 Top-Line Data for Investigational Osteoporosis Therapy Abaloparatide at the American Society for Bone and Mineral Research 2015 Annual Meeting
October 10, 2015 7:15 PM EDTWALTHAM, Mass., Oct. 10, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announces positive top-line data from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In... More
